SeaStar Medical Holding (ICU) 10-Q 13 Aug 24 2024 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2024	Jul. 31, 2024
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Entity Registrant Name	SEASTAR MEDICAL HOLDING CORPORATION
Entity Central Index Key	0001831868
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39927
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-3681132
Entity Address, Address Line One	3513 Brighton Blvd.,
Entity Address, Address Line Two	Suite 410
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80216
City Area Code	844
Local Phone Number	427-8100
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,168,972
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	ICU
Security Exchange Name	NASDAQ
Redeemable Warrants [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share
Trading Symbol	ICUCW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash	$ 1,179	$ 176
Prepaid expenses	1,235	2,132
Total current assets	2,414	2,308
Other assets	1,053	1,205
Total assets	3,467	3,513
Current liabilities
Accounts payable	4,117	4,372
Upfront payment for license agreement	0	100
Accrued expenses	2,258	1,523
Contract liabilities, current portion	112	0
Notes payable, net of deferred financing costs	3,140	565
Convertible notes, current portion	0	4,179
Liability classified warrants	303	2,307
Total current liabilities	9,930	13,046
Notes payable, net of deferred financing costs	0	4,143
Contract liabilities, net of current portion	438	0
Convertible notes, net of current portion	0	194
Total liabilities	10,368	17,383
Commitments and contingencies (Note 10)
Stockholders' deficit
Preferred stock - $0.0001 par value per share; 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023	0	0
Common stock - $0.0001 par value per share; 500,000,000 shares authorized; 3,221,104 and 1,904,611 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	1	1
Additional paid-in capital	123,765	100,863
Accumulated deficit	(130,667)	(114,734)
Total stockholders' deficit	(6,901)	(13,870)
Total liabilities, convertible preferred stock and stockholders' deficit	$ 3,467	$ 3,513

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	3,221,104	3,221,104
Common stock, shares outstanding	1,904,611	1,904,611

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating expenses
Research and development	$ 2,334	$ 1,981	$ 4,031	$ 3,711
General and administrative	2,335	1,769	4,588	4,620
Total operating expenses	4,669	3,750	8,619	8,331
Loss from operations	(4,669)	(3,750)	(8,619)	(8,331)
Other income (expense)
Interest income	25	0	25	0
Interest expense	(82)	(225)	(225)	(658)
Change in fair value of convertible notes	(387)	(100)	(6,145)	0
Change in fair value of warrants liability	1,880	723	(966)	759
Change in the fair value of the forward purchase agreement derivative liability	0	910	0	(1,308)
Total other income (expense), net	1,436	1,308	(7,311)	(1,207)
Loss before provision for income taxes	(3,233)	(2,442)	(15,930)	(9,538)
Provision for income taxes	3	5	3	5
Net loss	$ (3,236)	$ (2,447)	$ (15,933)	$ (9,543)
Net loss per share:
Net loss per share of common stock, basic	$ (1.03)	$ (4.1)	$ (5.36)	$ (17.06)
Net loss per share of common stock, diluted	$ (1.03)	$ (4.1)	$ (5.36)	$ (17.06)
Weighted-average shares outstanding - basic	3,154,782	597,315	2,975,248	559,385
Weighted-average shares outstanding - diluted	3,154,782	597,315	2,975,248	559,385

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2022	$ (20,762)	$ 1	$ 67,739	$ (88,502)
Beginning Balances (in shares) at Dec. 31, 2022		507,987
Issuance of shares - equity line of credit, Shares		15,120
Issuance of shares - equity line of credit	1,108		1,108
Issuance of shares - commitment fee for equity line of credit, Shares		8,754
Issuance of shares - commitment fee for equity line of credit	1,000		1,000
Issuance of shares - prepaid forward contracts (As restated)	1,870		1,870
Stock-based compensation	505		505
Net loss	(7,096)			(7,096)
Ending Balance at Mar. 31, 2023	(23,375)	$ 1	72,222	(95,598)
Ending Balances (in shares) at Mar. 31, 2023		531,861
Beginning Balance at Dec. 31, 2022	(20,762)	$ 1	67,739	(88,502)
Beginning Balances (in shares) at Dec. 31, 2022		507,987
Net loss	(9,543)
Ending Balance at Jun. 30, 2023	(11,757)	$ 1	86,287	(98,045)
Ending Balances (in shares) at Jun. 30, 2023		724,850
Beginning Balance at Mar. 31, 2023	(23,375)	$ 1	72,222	(95,598)
Beginning Balances (in shares) at Mar. 31, 2023		531,861
Issuance of shares - equity line of credit, Shares		1,080
Issuance of shares - equity line of credit	55		55
Issuance of shares - prepaid forward contracts, Shares		43,879
Issuance of shares - conversion of convertible notes, Shares		123,527
Issuance of shares - conversion of convertible notes	1,936		1,936
Issuance of shares - vesting of RSUs		6,136
Forward Purchase Agreement Derivative Liability	11,519		11,519
Stock-based compensation	555		555
Stock-based compensation, Shares		18,367
Net loss	(2,447)			(2,447)
Ending Balance at Jun. 30, 2023	(11,757)	$ 1	86,287	(98,045)
Ending Balances (in shares) at Jun. 30, 2023		724,850
Beginning Balance at Dec. 31, 2023	(13,870)	$ 1	100,863	(114,734)
Beginning Balances (in shares) at Dec. 31, 2023		2,016,078
Issuance of shares - conversion of convertible notes, Shares		507,912
Issuance of shares - conversion of convertible notes	9,389		9,389
Issuance of shares - exercise of warrants, Shares		352,074
Issuance of shares - exercise of warrants	3,959		3,959
Issuance of shares - equity offerings, net of issuance costs, Shares		252,182
Issuance of shares - equity offerings, net of issuance costs	8,309		8,309
Stock-based compensation	434		434
Net loss	(12,697)			(12,697)
Ending Balance at Mar. 31, 2024	(4,476)	$ 1	122,954	(127,431)
Ending Balances (in shares) at Mar. 31, 2024		3,128,246
Beginning Balance at Dec. 31, 2023	(13,870)	$ 1	100,863	(114,734)
Beginning Balances (in shares) at Dec. 31, 2023		2,016,078
Net loss	(15,933)
Ending Balance at Jun. 30, 2024	(6,901)	$ 1	123,765	(130,667)
Ending Balances (in shares) at Jun. 30, 2024		3,221,104
Beginning Balance at Mar. 31, 2024	(4,476)	$ 1	122,954	(127,431)
Beginning Balances (in shares) at Mar. 31, 2024		3,128,246
Issuance of shares - conversion of convertible notes, Shares		92,858
Issuance of shares - conversion of convertible notes	826		826
Issuance costs - registration of previously issued warrants	(56)		(56)
Stock-based compensation	41		41
Net loss	(3,236)			(3,236)
Ending Balance at Jun. 30, 2024	$ (6,901)	$ 1	$ 123,765	$ (130,667)
Ending Balances (in shares) at Jun. 30, 2024		3,221,104

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Cash flows from operating activities
Net loss	$ (3,236)	$ (2,447)	$ (15,933)	$ (9,543)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of deferred financing costs			57	23
Change in fair value of convertible notes (issued, converted and outstanding)			6,145	0
Change in fair value of forward purchase agreement derivative liability			0	1,308
Change in fair value of liability classified warrants (exercised and outstanding)	(1,880)	(723)	966	(759)
Stock-based compensation			475	1,060
Changes in operating assets and liabilities
Other receivables			0	12
Prepaid expenses			897	658
Other assets			152	0
Accounts payable			(255)	2,428
Accrued expenses			689	350
Other liabilities			495	0
Net cash used in operating activities			(6,312)	(4,463)
Cash flows from financing activities
Proceeds from issuance of convertible notes			979	5,000
Payment of convertible notes			(700)	(258)
Proceeds from issuance of shares			4,492	1,163
Proceeds from exercise of convertible note warrants			853	0
Proceeds of pre-funded warrants			3,766	0
Payment of commitment fee - equity line of credit			0	(500)
Proceeds from sale of recycled shares			0	1,870
Proceeds from notes payable			0	100
Payment of notes payable			(2,075)	(2,946)
Net cash provided by financing activities			7,315	4,429
Net increase / (decrease) in cash			1,003	(34)
Cash, beginning of period			176	47	$ 47
Cash, end of period	$ 1,179	$ 13	1,179	13	$ 176
Supplemental disclosure of cash flow information
Cash paid for interest			439	508
Exercise of liability classified warrants			3,106	0
Shares issued from conversion of convertible notes			10,210	0
Issuance of convertible note warrants			$ 586	$ 500

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (3,236)	$ (12,697)	$ (2,447)	$ (7,096)	$ (15,933)	$ (9,543)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false	false
Non-Rule 10b5-1 Arrangement Adopted	false	false
Rule 10b5-1 Arrangement Terminated	false	false
Non-Rule 10b5-1 Arrangement Terminated	false	false

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1. D e scription of Business Organization and description of business SeaStar Medical Holding Corporation, a Delaware corporation ("SeaStar") and its wholly owned subsidiary, SeaStar Medical, Inc., are collectively referred to as the "Company". SeaStar Medical, Inc. was incorporated as a Delaware corporation in June 2007, and it is headquartered in Denver, Colorado. The Company is a commercial stage medical technology company developing a proprietary platform therapy, its Selective Cytopheretic Device (“SCD”), to reduce the consequences of hyperinflammation on vital organs. The primary target of this technology is for the treatment of acute kidney injuries. The Company received FDA approval for our pediatric SCD on February 22, 2024, under a Humanitarian Device Exemption ("HDE"), and shipped it's first commercial units in July 2024 (see Note 14, Subsequent Events ). On October 28, 2022, LMF Merger Sub, Inc., a wholly owned subsidiary of LMF Acquisition Opportunities, Inc., (“LMAO”) merged with and into SeaStar Medical, Inc. (the "Business Combination"), with SeaStar Medical, Inc. surviving the Business Combination as a wholly owned subsidiary of LMAO. Following the consummation of the Business Combination, LMAO was renamed "SeaStar Medical Holding Corporation." Basis of presentation and consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC") for interim reporting. As permitted under those rules and regulations, certain notes or other financial information normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the Company’s results for the interim periods presented. The results from operations for the three and six months ended June 30, 2024, are not necessarily indicative of the results to be expected for the year ended December 31, 2024, or for any future annual or interim period. The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the related notes for the year ended December 31, 2023. There have been no material changes in our significant accounting policies as described in our Annual Report on Form 10-K for the year ended December 31, 2023 except for inclusion of the Company’s policy for revenue recognition, which is discussed in Note 2 of this Form 10-Q. The interim unaudited condensed consolidated financial statements include the consolidated accounts of the Company's wholly owned subsidiary, SeaStar Medical, Inc. All significant intercompany transactions have been eliminated in consolidation. On June 7, 2024, the Company effected a 1-for-25 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock , par value $ 0.0001 (the "common stock"). Following the effect of the Reverse Stock Split, every 25 shares of the Company’s common stock that were issued and outstanding automatically converted into one outstanding share of common stock . All stock options and warrants of the Company outstanding immediately prior to the Reverse Stock Split were proportionally adjusted except for the Listed Warrants and the private placement warrants that were issued as part of the SPAC transaction that closed on October 28, 2022, which total 16,788,000 outstanding warrants in the aggregate (the “Unadjusted Warrants”). The Unadjusted Warrants retained an $ 11.50 exercise price each and require the exercise of 25 warrants to purchase one share of common stock. Unless otherwise indicated, all other share and per share amounts in this quarterly report reflect the effect of the Reverse Stock Split. The par value of the Company’s common stock remained unchanged at $ 0.0001 per share and the number of authorized shares of common stock remained the same after the Reverse Stock Split. Segment information The Company operates in one operating segment and, accordingly, no segment disclosures have been presented herein. Liquidity and going concern As of June 30, 2024, the Company has an accumulated deficit of $ 130.7 million and cash of $ 1.2 million. We do not believe our cash will be sufficient to enable us to fund our operations, including clinical trial expenses and capital expenditure requirements for at least 12 months from the issuance of these unaudited interim condensed consolidated financial statements. We believe that these conditions raise substantial doubt about our ability to continue as a going concern. The Company's need for additional capital will depend in part on the scope and costs of its development activities. Through June 30, 2024, we had not generated any revenue from the sales of commercialized products. While the Company shipped its first commercial units of pediatric SCD devices in July 2024, the Company's ability to generate sufficient product revenue to generate positive operating cash flows will depend on the further successful development and eventual commercialization of the Company's pediatric SCD devices. Until such time, if ever, the Company expects to finance its operations through the sale of equity or debt, borrowing under credit facilities, through potential collaborations, other strategic transactions or grants. Adequate capital may not be available to the Company when needed or on acceptable terms. Risks and uncertainties The Company is subject to risks common to early-stage companies in the medical technology industry including, but not limited to, the success of its clinical trials, new medical and technological innovations, dependence on key personnel, supply of key components, protection of proprietary technology, and product liability. There can be no assurance that the Company's products or services will be accepted in the marketplace, nor can there be any assurance that any future products or services can be developed or deployed at an acceptable cost and with appropriate performance characteristics, or that such products or services will be successfully marketed, if at all. These factors could have a materially adverse effect on the Company's future financial results, financial position and cash flows.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period. Significant estimates include the valuation of the liability classified warrants, prepaid forward purchase agreement derivative liability, provision for income taxes, convertible debt measured at fair value, and the amount of stock-based compensation expense. Although actual results could differ from those estimates, such estimates are developed based on the best information available to management and management's best judgments at the time. Concentrations of credit risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows. Fair value of financial instruments The following provides a summary of those assets or liabilities for which the Company is required to measure at fair value either on a recurring basis, the valuation techniques and summary of inputs used to arrive at the measure of fair value. Changes in fair value of these assets or liabilities are recognized as a component of net income in the consolidated statements of operations. Changes in fair value of these assets or liabilities are considered unrealized gains or losses and therefore are classified as non-cash adjustments to reconcile net income to operating cash flows. Significant increases (decreases) in unobservable inputs used in fair value measurements could, in isolation, potentially result in a significantly lower or higher valuation for those assets or liabilities requiring recurring fair value measurements at each reporting date. The Company uses a Black-Scholes option pricing model to fair value warrants, using standard option pricing inputs such as the strike price of each warrant tranche, estimated volatility, time to maturity, and the risk-free interest rate. The risk-free interest rate is the U.S. Treasury rate at the date of issuance, and the time to maturity is based on the contractual life at the date of issuance, which is an interpolated value based on the remaining term of each individual instrument. The change in fair value of the liability classified warrants each reporting period is recorded to the change in fair value of warrants liability in the consolidated statements of operations. Revenue Recognition Under ASC Topic 606, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the Company evaluates the following criteria: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii)determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) performance obligations are satisfied. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct combined performance obligation is identified. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled, subject to the constraint on variable consideration. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as contract obligations. Amounts expected to be recognized as revenue within the one year following the balance sheet date are classified as current contract obligations. Amounts not expected to be recognized as revenue within the one year following the balance sheet date are classified as contract obligations, net of current portion. See Note 3 – Revenue and Contract Obligations for further details. Emerging growth company status The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 ("JOBS Act"). Under the JOBS Act, emerging growth companies can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. Recently issued accounting standards Accounting Standards Update 2023-09 — In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures . ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures. The amendments in this update are effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. We are currently assessing the impact of this guidance on our disclosures. Accounting Standards Update 2023-07 — In November 2023, the FASB issued Accounting Standards Update 2023-07 , Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This guidance improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses, and is effective for fiscal years beginning after December 15, 2023 on a retrospective basis. The Company is currently assessing the impact of this guidance on our disclosures, but does not expect adoption to have an impact on our consolidated financial statements.

Revenues and Contract Obligatio

Revenues and Contract Obligations	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenues and Contract Obligations	Note 3. Revenues and Contract Obligations In December 2022, the Company entered into a License and Distribution Agreement (the "Distribution Agreement") with a customer granting exclusive distribution rights of the Company's SCD device within the United States of America to the customer. Under the terms of the Distribution Agreement, the customer will pay the Company consideration comprising both a per unit sales price for each unit shipped and a royalty for all units sold by the customer. In addition, the customer also agreed to pay (i) a $ 0.1 million upfront payment at contract inception (the "Upfront Payment"), and (ii) two contingent milestones payments of (a) $ 0.5 regulatory milestone tied to receiving HDE approval from the FDA (the "Regulatory Milestone"), and (b) $ 0.3 million sales-based milestone (the "Sales Based Milestone"). The Company has the following performance obligations within the Distribution Agreement: (i) a material right to the customer for an exclusive option to purchase additional pediatric SCD devices during the term of the contract for a discounted price, (ii) provide training to medical professionals and (iii) upon each issuance of a purchase order, delivery of pediatric SCD devices. The transaction price for the material right and training is comprised of the Upfront payment, the Regulatory Milestone and the Sales Based Milestone. The transaction price for each pediatric SCD device sold will be the actual price for each device and the estimated royalties to be received. As of and for the six-months ended June 30, 2024, the Company had not shipped any pediatric SCD devices under the Distribution Agreement, and accordingly, had not recognized or reported any revenue. As of June 30, 2024, the Company received full consideration for the Upfront Payment and the Regulatory Milestone. No revenue had been recognized from this consideration as of June 30, 2024, and has been accounted for and disclosed as contract liabilities to be recognized over the remaining term of the Distribution Agreement beginning upon the first successful commercial shipment (see Note 14). The following table summarizes the changes in the Company's contract liability balance for the six months ended June 30, 2024 and 2023: Six Months Ended June 30, ($ in thousands) 2024 2023 Contract liabilities, beginning of period $ — $ — Consideration received and deferred 550 — Recognition of revenue included in beginning of period contract obligations — — Contract liabilities, end of period $ 550 $ — As of June 30, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was equal to the contract liability balance. The Company expects the following recognition of revenue from contract liabilities as of June 30, 2024: Fiscal Year Ending December 31, 2024 (remaining) $ 56 2025 112 2026 112 2027 112 2028 112 Thereafter 46 Total $ 550

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2024
Accrued Liabilities, Current [Abstract]
Accrued Expenses	Note 4. Accrued Expenses Accrued expenses consisted of the following amounts as of June 30, 2024 and December 31, 2023: ($ in thousands) As of As of Accrued bonus $ 856 $ 501 Accrued director compensation 610 427 Accrued research and development 502 507 Accrued legal 118 43 Accrued interest 75 19 Other 97 26 Total accrued expenses $ 2,258 $ 1,523

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2024
Notes Payable [Abstract]
Notes Payable	Note 5. Notes Payable Notes payable activity was as follows for the six month period ended June 30, 2024: ($ in thousands) LMFA LMFAO Maxim Insurance Financing Investor D Note Unamortized deferred financing costs Balance as of December 31, 2023 $ 296 $ 1,128 $ 2,771 $ 565 $ — $ ( 52 ) Note issued in exchange for warrants — — — — $ 450 — Payments ( 296 ) ( 1,128 ) ( 181 ) ( 420 ) — ( 50 ) Amortization of costs — — — — — 57 Balance as of June 30, 2024 $ — $ — $ 2,590 $ 145 $ 450 $ ( 45 ) Future maturities of principal repayment of the notes payable as of June 30, 2024 are as follows: Fiscal Year Ending December 31 2024 (remaining) $ 3,185 Thereafter — Total $ 3,185 Investor D Note On June 28, 2024, the Company and Investor D agreed to exchange all of the remaining outstanding warrants held by Investor D, which were issued in connection with Investor D's convertible debt issued between March 2023 and January 2024, into a short-term note of approximately $ 0.5 million. The interest rate on the loan is 7.0 % per annum and the note is due in full during the three-months ending September 30, 2024. Senior Secured LMFA Note Payable The company entered into a senior secured note with LMFA in September 2022. The interest rate on the loan was 7.0 % and was to mature on March 27, 2025 . The Company paid this note in full during quarter ended March 31, 2024. Senior Secured LMFAO Note Payable The company entered into a senior secured note with LMFAO in October 2022. The interest rate on the loan was 7.0 % and was to mature on March 27, 2025 . The Company paid this note in full during quarter ended March 31,2024. Unsecured Maxim Note Payable In October 2022, the Company entered into an unsecured promissory note with Maxim, for an aggregate principal amount of $ 4.2 million (the "Maxim Note"). The interest rate on the note is 7.0 % and remaining contractual balance is approximately $ 2.6 million as of June 30, 2024. As a result of the Reverse Stock Split, the Maxim Note became due within 90 days of the Reverse Stock Split event (see Note 14). Insurance Financing In October 2023, the Company entered into a financing arrangement with a lender to finance a portion of the annual premium of an insurance policy in the amount of $ 0.7 million. The Company will pay the remaining two monthly installments of principal and interest with the last payment being made in August 2024 .

Convertible Notes

Convertible Notes	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Convertible Notes	Note 6. Convertible Notes The activity for the convertible notes is disclosed in the table below for the six month period ended June 30, 2024. See our Annual Report on Form 10-K for the year-ended for December 31, 2023, for other details relating to the Investor D convertible notes issued prior to December 31, 2023. ($ in thousands) 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 4th Investor D Note 5th Investor D Note 6th Investor D Note Total Balance as of December 31, 2023 $ 1,012 $ 999 $ 972 $ 568 $ 822 $ — $ — $ 4,373 Issuance (Face Value) — — — — — 272 815 1,087 Fair value of detachable warrants at issuance — — — — — ( 147 ) ( 439 ) ( 586 ) (Gain)/loss on conversion 1,201 636 615 381 77 482 2,005 5,397 Conversion to common stock ( 2,213 ) ( 1,635 ) ( 1,587 ) ( 949 ) ( 947 ) ( 607 ) ( 2,381 ) ( 10,319 ) (Gain)/loss on reporting period remeasurement — — — — 748 — — 748 Redemption — — — — ( 700 ) — — ( 700 ) Balance as of June 30, 2024 $ — $ — $ — $ — $ — $ — $ — — The Company completed additional closings related to the Second Amendment to the Investor D Securities Purchase Agreement on January 12, 2024 and January 24, 2024, issuing notes in principal amounts of $ 0.3 million and $ 0.8 million, respectively, each at 7.00 % per annum (collectively the "2024 Investor D Notes"). The 2024 Investor D Notes were to mature on April 12, 2025 and April 24, 2025 , respectively. The 2024 Investor D Notes have an initial conversion price of $ 14.00 per share and were convertible into shares of the Company's common stock, beginning on the earlier of June 11, 2024 (or earlier upon mutual written agreement of the Company and the purchaser), or the date of an event of default. The Company also issued warrants to purchase up to 5,278 and 15,382 shares of common stock, respectively, with an exercise price of $ 14.00 per share, and additional warrants to purchase up to 5,278 and 15,382 shares of common stock, respectively, with an exercise price of $ 14.00 per share. On January 30, 2024, the institutional investor agreed to waive its Optional Redemption Rights and any event of default that may arise thereunder with respect to this offering and suspend the Optional Redemption Rights for a period of sixty ( 60 ) days following the closing of this offering (the “Suspension Period”), and the Company granted the institutional investor a right to redeem all or a portion of the then outstanding Conversion Amount within three (3) trading days after the Suspension Period at an amount equal to 200 % of the Conversion Amount. During the quarter-ended March 31, 2024, the institutional investor converted approximately $ 3.3 million (face value) of outstanding debt, by converting the outstanding debt into approximately $ 9.5 million of the Company's common stock. As of March 31, 2024, the Company still owed the institutional investor approximately $ 1.0 million (face value) in convertible debt, with a fair value of approximately $ 1.1 million. The Company incurred a loss of approximately $ 5.8 million as a result of the following: (i) $ 4.7 million loss on conversion into equity as a result of the difference between the fair value of the convertible notes being converted and the equity being delivered, (ii) $ 0.7 million losses on issuance of the Investor D convertible notes issued during the three-months ended March 31, 2024, as a result of the combination of the fair value of detachable warrants issued in conjunction to the Investor D Notes issues during the three-months ended March 31, 2024, and the excess fair value over the proceeds received for the Investor D convertible notes issues during the three-months ended March 31, 2024, and (iii) $ 0.4 million loss on the change in fair value of those Investor D convertible notes still outstanding as of March 31, 2024. Investor D April 2024 Side Letter On April 1, 2024, the Company and Investor D entered into a side letter agreement (the "April 2024 Side Letter") whereby each party agreed to suspend certain rights of Investor D for a 60 day period, extending those rights from March 30, 2024, to May 30, 2024. Those rights included a 10 day notice period for any subsequent financing and rights to review terms of such financing arrangements. Finally, Investor D waived its rights and notice of default in the event of such financings. In addition, after the end to the May 30, 2024, suspension period being reached, Investor D has the right to require the Company to redeem all or a portion of any outstanding Investor D convertible notes at 200 % of the conversion amount (the "Make-Whole Amount"). On June 5, 2024, Investor D completed the following two transactions, eliminating the remaining outstanding convertible debt: • Converted approximately $ 0.6 million of outstanding principal and $ 0.7 million of accrued interest and Make-Whole Amount , by issuing 92,858 shares of the Company's common stock, resulting in a loss of approximately $ 0.4 million, and • Redeemed the remaining $ 0.7 million of outstanding convertible debt and Make-Whole Amount, and • As of June 30, 2024, there was no remaining outstanding convertible debt.

Equity Transactions

Equity Transactions	6 Months Ended
	Jun. 30, 2024
Stockholders' Equity Note [Abstract]
Equity Transactions	Note 7. Equity Transactions On January 26, 2024, the Company entered into a Securities Purchase Agreement with a single institutional investor, pursuant to which the Company issued to the Purchaser (the "Q1 2024 SPA"), (i) in a registered direct offering, 252,182 shares of the Company’s common stock, par value $ 0.0001 per share, and pre-funded warrants to purchase 181,449 shares of Common Stock with an exercise price of $ 0.0001 per share, and (ii) in a concurrent private placement, series A warrants to purchase 433,631 shares of common stock (the "Series A Common Warrants") and series B warrants to purchase 216,816 shares of common stock each with an exercise price of $ 20.76 (the "Series B Common Warrants" and together with the Series A Common Warrants, the "Investor E Warrants"). Such registered direct offering and concurrent private placement are referred to herein as the “Transactions.” The Company received aggregate gross proceeds from the Transactions of approximately $ 9.0 million, before deducting fees to the Maxim Group LLC and other estimated offering expenses payable by the Company. The Investor E Warrants will be exercisable commencing on the effective date of stockholder approval for the issuance of the shares of common stock issuable upon exercise of the Investor E Warrants. The Series A Common Warrants will expire on the fifth anniversary of the Stockholder Approval Date and the Series B Common Warrants will expire on the 12 month anniversary of the Stockholder Approval Date. The Pre-Funded Warrants will not expire and will be exercisable commencing on January 26, 2024, and at any time until all of the Pre-Funded Warrants are exercised in full. All Pre-Funded Warrants were exercised during the first quarter ended March 31, 2024. The Company paid approximately $ 0.7 million in fees to Maxim Group LLC and issued 21,682 warrants (the "PA Warrants") to purchase shares of the Company's common stock, with a fair value of approximately $ 0.3 million at issuance. The exercise price of these warrants is $ 22.83 per share and the warrants become exercisable on July 30, 2024 , expiring five years after the closing date. Tumin Equity Line of Credit During the year ended December 31, 2023, the Company sold 6,500,000 shares of common stock to Tumim for proceeds of approximately $ 4.7 million as part of the Tumin Equity Line of Credit (see the Company's Annual Report on Form 10-K for the year-ended December 31, 2023, for additional information on the structure and purpose). As of December 31, 2023, approximately $ 95.3 million was available to draw. In February 2024, the Company and Tumim agreed to terminate the Equity Line of Credit.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2024
Warrants and Rights Note Disclosure [Abstract]
Warrants	Note 8. Warrants Warrants Issued in FY 2024 Investor D Warrants The Company, in conjunction with additional borrowing of convertible debt related to the Second Amendment to the Investor D SPA on January 12, 2024 and January 24, 2024, issued warrants to purchase up to 131,927 and 395,781 shares of common stock, respectively, with an exercise price of $ 0.56 per share, and an additional warrants to purchase up to 131,927 and 395,781 shares of common stock, respectively, with an exercise price of $ 0.56 per share. All remaining Investor D Warrants issued in connection with the Investor D SPA were exchanged for approximately $ 0.5 million short-term note payable on June 28, 2024, eliminating all remaining Investor D Warrants issued in connection with the Investor D SPA as of June 30, 2024. Investor E Warrants As discussed in Note 7, as part of the Q1 2024 SPA, the Company issued on January 26, 2024 the following warrants to purchase the Company's common stock to Investor E: • Pre-Funded Warrants - warrants to purchase 181,449 shares of common stock with an exercise price of $ 0.0001 . The Pre-Funded Warrants had no expiration date and were exercisable commencing on the date of issuance and at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants were exercised in full during the quarter ended March 31, 2024 • Series A and Series B Warrants - in a concurrent private placement, Series A Common Warrants to purchase 433,631 shares of Common Stock and Series B Common Warrants to purchase 216,816 shares of common stock each with an exercise price of $ 20.76 . • PA Warrants – in a concurrent private placement, PA Warrants to purchase 21,682 shares of common stock with an exercise price of $ 22.83 per share. Investor E Warrants became exercisable on the effective date of stockholder approval for the issuance of the shares of common stock issuable upon exercise of the Investor E Warrants. The Series A Common Warrants will expire on the fifth anniversary of the Stockholder Approval Date and the Series B Common Warrants will expire on the 12-month anniversary of the Stockholder Approval Date. Maxim Group LLC acted as the placement agent in connection with the Transactions pursuant to the Placement Agency Agreement, dated January 26, 2024, by and between the Company and the Placement Agent. On January 30, 2024, the Placement Agent received warrants to purchase 21,682 shares of common stock covering a number of shares equal to 5 % of the total number of shares of common stock sold in the Transactions. The Placement Agent Warrants become exercisable commencing six months after the closing and will expire on January 30, 2029 . The PA Warrants are exercisable at a price equal to 110.0 % of the offering price in connection with the placement. In accordance with ASC 815-40, Derivatives and Hedging-Contracts in Entity’s own Equity , the Company determined the Investor E and PA Warrants meet the conditions for equity classification, and should be carried on the consolidated balance sheets as a component of stockholders' equity (deficit). The Investor D Warrants issued in January 2024 in connection with the Investor D SPA were determined to be liability classified. The initial fair value of the convertible note warrants was determined using a Black-Scholes option pricing model, which considers variables such as estimated volatility, time to maturity, and the risk-free interest rate. The risk-free interest rate is the U.S. Treasury rate at the date of issuance, and the time to maturity is based on the contractual life at the date of issuance, which is five years. Subsequent changes in fair value were recognized through earnings at each reporting period end-date or settlement date. The Company had the following warrants outstanding at June 30, 2024 and December 31, 2023: As of As of Liability Classified Warrants Investor D Warrants — 254,732 Private Placement Warrants 229,520 229,520 PIPE Investor Warrants 20,000 20,000 Subtotal 249,520 504,252 Equity Classified Warrants Investor E Warrants 650,446 — Placement Agent Warrants 21,682 — Public Stockholder Warrants 422,000 422,000 Legacy Warrants 1,957 1,957 Subtotal 1,096,085 423,957 Grand Total 1,345,605 928,209 The following tables provides the weighted-average strike price and time to maturity for each warrant tranche as of June 30, 2024 and December 31, 2023: As of June 30, 2024 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Expiration Liability Classified Warrants Private Placement Warrants 229,520 $ 287.50 3.32 PIPE Investor Warrants 20,000 $ 287.50 3.32 Equity Classified Warrants Investor E Warrants 650,446 $ 20.76 4.93 Placement Agent Warrants 21,682 $ 22.75 4.58 Public Stockholder Warrants 422,000 $ 287.50 3.33 Legacy SeaStar Inc. Warrants 1,957 $ 250.00 1.88 As of December 31, 2023 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Expiration Liability Classified Warrants Investor D Warrants 254,732 $ 12.50 4.65 Private Placement Warrants 229,520 $ 287.50 3.82 PIPE Investor Warrants 20,000 $ 287.50 3.82 Equity Classified Warrants Public Stockholder Warrants 422,000 $ 287.50 3.82 Legacy SeaStar Inc. Warrants 1,957 $ 250.00 2.38 Below is the warrant activity for the six-months ended June 30, 2024: Investor D Warrants Investor E Warrants Placement Agent Warrants Private Placement Warrants PIPE Investor Warrants Public Stockholders' Warrants Legacy Warrants Outstanding as of December 31, 2023 254,732 — - 229,520 20,000 422,000 1,957 Issuance 42,217 831,895 21,682 — — — — Exercised ( 170,625 ) ( 181,449 ) - — — — — Forfeited / cancelled — — - — — — — Exchanged for Investor D Note ( 126,324 ) — — — — — — Outstanding as of June 30, 2024 - 650,446 21,682 229,520 20,000 422,000 1,957 During the three months ended June 30, 2024, the Company exchanged all outstanding warrants with Investor D; that were issued in connection with the convertible notes issued by the Company from March 2023 through January 2024 (see Note 6); for an approximately $ 0.5 million short-term Investor D Note. The Company recognized a gain of approximately $ 1.3 million upon the exchange. The Company recognized an unrealized gain of approximately $ 0.6 million due to the change in the fair value of the remaining liability classified warrants. During the six months ended June 30, 2024, the Company incurred $ 1.6 million from losses on exercises of certain Investor D Warrants, a gain of $ 1.3 million from the aforementioned exchange with Investor D, and a loss of approximately $ 0.6 million from the mark-to-market adjustment for all remaining liability classified warrants.

Stock-Based Compensation Awards

Stock-Based Compensation Awards	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation Awards	Note 9. Stock-Based Compensation Awards The following table sets forth the total stock-based compensation cost included in the Company's condensed consolidated statements of operations for the period indicated: Three Months Ended June 30, Six Months Ended June 30, ($ in thousands) 2024 2023 2024 2023 Research and development $ ( 7 ) $ 96 $ 112 $ 135 General and administrative 48 459 363 925 Total stock-based compensation $ 41 $ 555 $ 475 $ 1,060 Equity Incentive Plan - Summary 2022 Omnibus Incentive Plan The Company's Board of Directors adopted, and the shareholders approved the 2022 Omnibus Incentive Plan to provide long-term incentive for its employees and non-employee service providers. The vesting of stock options is stated in each individual grant agreement, which is generally either one or four years . Options granted expire 10 years after the date of grant. 2019 Stock Incentive Plan The Company’s Board of Directors adopted the 2019 Stock Incentive Plan on February 25, 2019, to provide long-term incentive for its employees and non-employee service providers. The Stock Incentive Plan was terminated on October 28, 2022, and no further awards were granted under such plan. Stock Options Option activity for the period ended June 30, 2024, is as follows: 2022 Omnibus Incentive Plan - Stock Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding as of December 31, 2023 14,045 $ 46.00 $ — 8.8 Exercised — Issued — Forfeited / cancelled ( 266 ) Outstanding at June 30, 2024 13,779 $ 46.00 $ — 8.8 Vested and exercisable as of June 30, 2024 13,779 $ — $ — 8.8 2019 Omnibus Incentive Plan - Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding as of December 31, 2023 9,792 $ 46.00 $ — 6.4 Exercised — Issued — Forfeited / cancelled ( 160 ) Outstanding as of June 30, 2024 9,632 $ 46.00 $ — 6.2 Vested and exercisable as of June 30, 2024 8,874 $ 46.00 $ — 6.2 Restricted Stock Units A summary of the Company’s restricted stock unit (‘RSU”) activity is as follows: 2022 Omnibus Incentive Plan - RSUs Number of RSU Weighted-Average Grant Date Fair Value (per share) Outstanding as of December 31, 2023 9,372 $ 36.75 Granted 38,000 Vested ( 9,194 ) Forfeited / cancelled ( 178 ) Outstanding as of June 30, 2024 38,000 $ 17.93 2019 Stock Incentive Plan - RSUs Number of RSU Weighted-Average Grant Date Fair Value (per share) Outstanding as of December 31, 2023 3,698 $ 200.00 Exercised - Vested ( 1,278 ) Forfeited / cancelled ( 352 ) Outstanding as of June 30, 2024 2,068 $ 200.00

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10. Commitments and Contingencies Lease agreements The Company is part of a membership agreement for shared office space and can cancel at any time. Rent expense was approximately $ 8 and $ 16 thousand for the three- and six- months ended June 30, 2024 and 2023, respectively. Litigation Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. In connection with the Business Combination, LMAO proposed, for stockholder approval, various amendments to its Amended and Restated Certificate of Incorporation, which included among other things a proposal to increase the authorized shares of common stock. A purported stockholder sent a Stockholder Litigation Demand letter (the “Demand”) to the Board of Directors of LMAO alleging that the Delaware General Corporation Law required a separate class vote of the Class A common stockholders to increase the authorized shares of common stock. Following receipt of the Demand, the Company canceled and withdrew the proposal to increase the authorized shares of common stock. The stockholder’s counsel thereafter demanded that the Company pay counsel fees for the purported benefit conferred upon the Company’s shareholders by causing the Company to withdraw the allegedly invalid proposal to increase the authorized shares of common stock. The Company paid approximately $ 0.2 million for a legal settlement during the year ended December 31, 2023, and this matter has been closed.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 11. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: Level 1 – quoted prices in active markets for identical assets and liabilities. Level 2 – other significant observable inputs (including quoted prices for similar assets and liabilities, interest rate, credit risk, etc.). Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities). The fair value of the forward option on prepaid forward contracts, convertible notes, and the warrants liability is classified as Level 3 in the fair value hierarchy. Fair Value Measurement Hierarchy The following table presents the Company's financial assets and/or liabilities that were accounted for at fair value on a recurring basis as of June 30, 2024 and December 31, 2023, by level within the fair value hierarchy. There were no non-recurring fair value measurements, as the Company does not have any long-lived assets, including fixed assets, intangible assets or goodwill which can require non-recurring measurements for impairment. Fair Value Measurements as of June 30, 2024 (Level 1) (Level 2) (Level 3) Total Liabilities: Convertible notes $ — $ — $ — $ — Liability classified warrants — — 303 303 $ — $ — $ 303 $ 303 Fair Value Measurements as of December 31, 2023 (Level 1) (Level 2) (Level 3) Total Liabilities: Convertible notes $ — $ — $ 4,179 $ 4,179 Liability classified warrants — — 2,307 2,307 Total $ — $ — $ 6,486 $ 6,486 Summary of Level 3 Input Changes The following table presents the changes in the forward option-prepaid forward contracts, convertible notes measured at fair value, warrants liability, and the notes derivative liability for the periods ended June 30, 2024 and December 31, 2023 (in thousands): Level 3 Roll Forward Convertible Notes Liability Classified Warrants Balance as of December 31, 2023 $ 4,373 $ 2,307 Additions 501 586 Cash paid to settle ( 700 ) — Exchange for short-term note payable — ( 450 ) Shares issued upon conversion or exercise ( 4,922 ) ( 3,106 ) Changes in fair value 748 966 Balance as of June 30, 2024 $ — $ 303 Level 3 Inputs For assets or liabilities for which the Company is required to remeasure the fair value on a recurring basis at each reporting date, generally the Company is required to disclose certain quantitative data related to the inputs used at the most recent reporting period date. However, for those assets or liabilities for which the Company has elected to take the FVO in accordance with ASC 825, Financial Instruments , then such quantitative disclosures are not required. Liability Classified Warrants The liability classified warrants as of June 30, 2024 and December 31, 2023, include three classes of warrants, and therefore, the range of assumptions used has been provided. Significant assumptions used in valuing warrants which require liability classification were as follows as of June 30, 2024 and December 31, 2023. As of June 30, 2024 Expected volatility 115.00 % Equivalent term (#) 3.33 Risk-free rate 4.37 % Dividend yield 0.00 % Stock price $ 7.59 Strike price (#) $ 287.50 As of December 31, 2023 Minimum Maximum Expected volatility 85.00 % 90.00 % Equivalent term 4.04 4.65 Risk-free rate 3.84 % 3.90 % Dividend yield 0.00 % 0.00 % Stock price $ 0.44 $ 0.44 Strike price $ 0.50 $ 11.50

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 12. Income Taxes In accordance with U.S. GAAP, a valuation allowance should be provided if it is more likely than not that some or all of the Company’s deferred tax assets will not be realized. The Company’s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Except as noted below, due to the uncertainty of future profitable operations and taxable income, the Company has recorded a full valuation allowance against its net deferred tax assets. The Company has recognized an insignificant provision for certain minimum state taxes of less than $ 0.1 million as of June 30, 2024, and December 31, 2023. The Company believes its tax filing position and deductions related to tax periods subject to examination will be sustained under audit and, therefore, has no reserve for uncertain tax positions.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	Note 13. Net Loss Per Share The following table presents the calculation of basic and diluted net loss per share (in thousands except share and per share information): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss $ ( 3,236 ) $ ( 2,447 ) $ ( 15,933 ) $ ( 9,543 ) Weighted-average shares outstanding - basic and diluted 3,154,782 597,315 2,975,248 559,385 Basic and diluted net loss per share $ ( 1.03 ) $ ( 4.10 ) $ ( 5.36 ) $ ( 17.06 ) The following weighted-average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive: As of June 30, 2024 2023 Investor D warrants — 21,891 Investor E warrants 650,446 — Placement Agent warrants 21,682 — Public Stockholders' warrants 422,000 422,000 Private Placement warrants 229,520 229,520 PIPE Investor warrants 20,000 20,000 Legacy warrants 1,957 1,957 Employee based options to purchase common stock 22,653 23,833 Unvested employee based restricted stock units 40,068 8,741 Total 1,408,326 727,942

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events Registered Direct Offering On July 10, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market consistent with the rules of the Nasdaq Stock Market (the “Registered Direct Offering”): (i) 947,868 shares (the “Shares”) of the Company’s common stock and (ii) common stock purchase warrants to purchase up to 947,868 shares of common stock (the “Common Warrants”) in a concurrent private placement (the “Concurrent Private Placement” and together with the Registered Direct Offering, the “Offering”). The Common Warrants are immediately exercisable, will expire five years following the issuance date and have an exercise price of $ 10.55 per share. The Company has agreed to register the shares of common stock underlying the Common Warrants within 30 days of the date of the Purchase Agreement. The combined purchase price of each share of common stock and Common Warrant is $ 10.55 . The gross proceeds to the Company from the Offering are approximately $ 10.0 million, before deducting placement agent fees and other offering expenses payable by the Company. Stockholder Litigation On July 5, 2024, Forrest A K Wells (the “Plaintiff”), a purported stockholder of SeaStar Medical Holding Corporation, a Delaware Corporation (the “Company’), filed a putative class action complaint in the United States District Court for the State of Colorado (the “Class Action”), alleging that the Company and its management members made material misstatements or omissions regarding the Company’s business and operations, including disclosures relating to FDA approval of product candidates of the Company, allegedly culminating in the restatement of the Company’s consolidated financial statements as disclosed in the Form 8-K filed on March 27, 2024. The Class Action asserts claims under Section 10(b) of the Exchange Act against the Company, its Chief Executive Officer and former Chief Financial Officer (collectively, the Defendants”), as well as claims under Section 20(a) of the Exchange Act against the Defendants. Among other remedies, the Class Action seeks to recover compensatory and other damages. The Company intends to vigorously defend the action. The Company has not recognized a contingent liability for this Class Action event as it does not qualify for the recognition criteria under ASC 450 - Contingencies. Commercialization of the Pediatric SCD Device In July 2024, the Company shipped its first pediatric SCD units, representing the Company's first commercial sale. This will allow the Company to recognize revenues from commercial activities for units sold, including revenue from contract liabilities (see Note 3). Maxim Note Payable Payment As a result of the June 7, 2024 Investor D convertible debt redemption and conversion, the Maxim Note became due within 90 days of the redemption and conversion. In addition, due to the July 2024 Registered Direct Offering described above in this Note 14, the Company was required to paid down $ 2.5 million of the outstanding Maxim Note in July 2024 leaving a remaining balance of approximately $ 0.1 million due before September 7, 2024.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Use of Estimates	Use of estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period. Significant estimates include the valuation of the liability classified warrants, prepaid forward purchase agreement derivative liability, provision for income taxes, convertible debt measured at fair value, and the amount of stock-based compensation expense. Although actual results could differ from those estimates, such estimates are developed based on the best information available to management and management's best judgments at the time.
Concentrations of credit risk	Concentrations of credit risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.
Fair value of financial instruments	Fair value of financial instruments The following provides a summary of those assets or liabilities for which the Company is required to measure at fair value either on a recurring basis, the valuation techniques and summary of inputs used to arrive at the measure of fair value. Changes in fair value of these assets or liabilities are recognized as a component of net income in the consolidated statements of operations. Changes in fair value of these assets or liabilities are considered unrealized gains or losses and therefore are classified as non-cash adjustments to reconcile net income to operating cash flows. Significant increases (decreases) in unobservable inputs used in fair value measurements could, in isolation, potentially result in a significantly lower or higher valuation for those assets or liabilities requiring recurring fair value measurements at each reporting date. The Company uses a Black-Scholes option pricing model to fair value warrants, using standard option pricing inputs such as the strike price of each warrant tranche, estimated volatility, time to maturity, and the risk-free interest rate. The risk-free interest rate is the U.S. Treasury rate at the date of issuance, and the time to maturity is based on the contractual life at the date of issuance, which is an interpolated value based on the remaining term of each individual instrument. The change in fair value of the liability classified warrants each reporting period is recorded to the change in fair value of warrants liability in the consolidated statements of operations.
Revenue Recognition	Revenue Recognition Under ASC Topic 606, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the Company evaluates the following criteria: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii)determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) performance obligations are satisfied. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct combined performance obligation is identified. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled, subject to the constraint on variable consideration. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as contract obligations. Amounts expected to be recognized as revenue within the one year following the balance sheet date are classified as current contract obligations. Amounts not expected to be recognized as revenue within the one year following the balance sheet date are classified as contract obligations, net of current portion. See Note 3 – Revenue and Contract Obligations for further details.
Emerging growth company status	Emerging growth company status The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 ("JOBS Act"). Under the JOBS Act, emerging growth companies can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.
Recently issued accounting standards	Recently issued accounting standards Accounting Standards Update 2023-09 — In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures . ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures. The amendments in this update are effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. We are currently assessing the impact of this guidance on our disclosures. Accounting Standards Update 2023-07 — In November 2023, the FASB issued Accounting Standards Update 2023-07 , Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This guidance improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses, and is effective for fiscal years beginning after December 15, 2023 on a retrospective basis. The Company is currently assessing the impact of this guidance on our disclosures, but does not expect adoption to have an impact on our consolidated financial statements.

Revenues and Contract Obligat_2

Revenues and Contract Obligations (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Summary of Changes in Contract Liability	The following table summarizes the changes in the Company's contract liability balance for the six months ended June 30, 2024 and 2023: Six Months Ended June 30, ($ in thousands) 2024 2023 Contract liabilities, beginning of period $ — $ — Consideration received and deferred 550 — Recognition of revenue included in beginning of period contract obligations — — Contract liabilities, end of period $ 550 $ —
Summary of Contract Liabilities by Performance Obligation and Expected Recognition of Revenue from Contract Liabilities	The Company expects the following recognition of revenue from contract liabilities as of June 30, 2024: Fiscal Year Ending December 31, 2024 (remaining) $ 56 2025 112 2026 112 2027 112 2028 112 Thereafter 46 Total $ 550

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2024
Accrued Liabilities, Current [Abstract]
Summary of Accrued Expenses	Accrued expenses consisted of the following amounts as of June 30, 2024 and December 31, 2023: ($ in thousands) As of As of Accrued bonus $ 856 $ 501 Accrued director compensation 610 427 Accrued research and development 502 507 Accrued legal 118 43 Accrued interest 75 19 Other 97 26 Total accrued expenses $ 2,258 $ 1,523

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2024
Notes Payable [Abstract]
Summary of Notes Payable	Notes payable activity was as follows for the six month period ended June 30, 2024: ($ in thousands) LMFA LMFAO Maxim Insurance Financing Investor D Note Unamortized deferred financing costs Balance as of December 31, 2023 $ 296 $ 1,128 $ 2,771 $ 565 $ — $ ( 52 ) Note issued in exchange for warrants — — — — $ 450 — Payments ( 296 ) ( 1,128 ) ( 181 ) ( 420 ) — ( 50 ) Amortization of costs — — — — — 57 Balance as of June 30, 2024 $ — $ — $ 2,590 $ 145 $ 450 $ ( 45 )
Schedule of Future Maturities of Principal Repayment of Convertible Notes	Future maturities of principal repayment of the notes payable as of June 30, 2024 are as follows: Fiscal Year Ending December 31 2024 (remaining) $ 3,185 Thereafter — Total $ 3,185

Convertible Notes (Tables)

Convertible Notes (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Instrument [Line Items]
The Activity for the Convertible Notes	The activity for the convertible notes is disclosed in the table below for the six month period ended June 30, 2024. See our Annual Report on Form 10-K for the year-ended for December 31, 2023, for other details relating to the Investor D convertible notes issued prior to December 31, 2023. ($ in thousands) 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 4th Investor D Note 5th Investor D Note 6th Investor D Note Total Balance as of December 31, 2023 $ 1,012 $ 999 $ 972 $ 568 $ 822 $ — $ — $ 4,373 Issuance (Face Value) — — — — — 272 815 1,087 Fair value of detachable warrants at issuance — — — — — ( 147 ) ( 439 ) ( 586 ) (Gain)/loss on conversion 1,201 636 615 381 77 482 2,005 5,397 Conversion to common stock ( 2,213 ) ( 1,635 ) ( 1,587 ) ( 949 ) ( 947 ) ( 607 ) ( 2,381 ) ( 10,319 ) (Gain)/loss on reporting period remeasurement — — — — 748 — — 748 Redemption — — — — ( 700 ) — — ( 700 ) Balance as of June 30, 2024 $ — $ — $ — $ — $ — $ — $ — —

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2024
Warrants and Rights Note Disclosure [Abstract]
Schedule of Warrants Outstanding	The Company had the following warrants outstanding at June 30, 2024 and December 31, 2023: As of As of Liability Classified Warrants Investor D Warrants — 254,732 Private Placement Warrants 229,520 229,520 PIPE Investor Warrants 20,000 20,000 Subtotal 249,520 504,252 Equity Classified Warrants Investor E Warrants 650,446 — Placement Agent Warrants 21,682 — Public Stockholder Warrants 422,000 422,000 Legacy Warrants 1,957 1,957 Subtotal 1,096,085 423,957 Grand Total 1,345,605 928,209
Schedule of Weighted-Average Strike Price and Time to Maturity for Each Warrant Tranche	The following tables provides the weighted-average strike price and time to maturity for each warrant tranche as of June 30, 2024 and December 31, 2023: As of June 30, 2024 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Expiration Liability Classified Warrants Private Placement Warrants 229,520 $ 287.50 3.32 PIPE Investor Warrants 20,000 $ 287.50 3.32 Equity Classified Warrants Investor E Warrants 650,446 $ 20.76 4.93 Placement Agent Warrants 21,682 $ 22.75 4.58 Public Stockholder Warrants 422,000 $ 287.50 3.33 Legacy SeaStar Inc. Warrants 1,957 $ 250.00 1.88 As of December 31, 2023 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Expiration Liability Classified Warrants Investor D Warrants 254,732 $ 12.50 4.65 Private Placement Warrants 229,520 $ 287.50 3.82 PIPE Investor Warrants 20,000 $ 287.50 3.82 Equity Classified Warrants Public Stockholder Warrants 422,000 $ 287.50 3.82 Legacy SeaStar Inc. Warrants 1,957 $ 250.00 2.38
Schedule of Warrant Activity	Below is the warrant activity for the six-months ended June 30, 2024: Investor D Warrants Investor E Warrants Placement Agent Warrants Private Placement Warrants PIPE Investor Warrants Public Stockholders' Warrants Legacy Warrants Outstanding as of December 31, 2023 254,732 — - 229,520 20,000 422,000 1,957 Issuance 42,217 831,895 21,682 — — — — Exercised ( 170,625 ) ( 181,449 ) - — — — — Forfeited / cancelled — — - — — — — Exchanged for Investor D Note ( 126,324 ) — — — — — — Outstanding as of June 30, 2024 - 650,446 21,682 229,520 20,000 422,000 1,957

Stock-Based Compensation Awar_2

Stock-Based Compensation Awards (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock-based Compensation Expense	The following table sets forth the total stock-based compensation cost included in the Company's condensed consolidated statements of operations for the period indicated: Three Months Ended June 30, Six Months Ended June 30, ($ in thousands) 2024 2023 2024 2023 Research and development $ ( 7 ) $ 96 $ 112 $ 135 General and administrative 48 459 363 925 Total stock-based compensation $ 41 $ 555 $ 475 $ 1,060
2022 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Option activity	2022 Omnibus Incentive Plan - Stock Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding as of December 31, 2023 14,045 $ 46.00 $ — 8.8 Exercised — Issued — Forfeited / cancelled ( 266 ) Outstanding at June 30, 2024 13,779 $ 46.00 $ — 8.8 Vested and exercisable as of June 30, 2024 13,779 $ — $ — 8.8
Summary of RSU Activity	A summary of the Company’s restricted stock unit (‘RSU”) activity is as follows: 2022 Omnibus Incentive Plan - RSUs Number of RSU Weighted-Average Grant Date Fair Value (per share) Outstanding as of December 31, 2023 9,372 $ 36.75 Granted 38,000 Vested ( 9,194 ) Forfeited / cancelled ( 178 ) Outstanding as of June 30, 2024 38,000 $ 17.93
2019 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Option activity	2019 Omnibus Incentive Plan - Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding as of December 31, 2023 9,792 $ 46.00 $ — 6.4 Exercised — Issued — Forfeited / cancelled ( 160 ) Outstanding as of June 30, 2024 9,632 $ 46.00 $ — 6.2 Vested and exercisable as of June 30, 2024 8,874 $ 46.00 $ — 6.2
Summary of RSU Activity	2019 Stock Incentive Plan - RSUs Number of RSU Weighted-Average Grant Date Fair Value (per share) Outstanding as of December 31, 2023 3,698 $ 200.00 Exercised - Vested ( 1,278 ) Forfeited / cancelled ( 352 ) Outstanding as of June 30, 2024 2,068 $ 200.00

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company's financial assets and/or liabilities that were accounted for at fair value on a recurring basis as of June 30, 2024 and December 31, 2023, by level within the fair value hierarchy. There were no non-recurring fair value measurements, as the Company does not have any long-lived assets, including fixed assets, intangible assets or goodwill which can require non-recurring measurements for impairment. Fair Value Measurements as of June 30, 2024 (Level 1) (Level 2) (Level 3) Total Liabilities: Convertible notes $ — $ — $ — $ — Liability classified warrants — — 303 303 $ — $ — $ 303 $ 303 Fair Value Measurements as of December 31, 2023 (Level 1) (Level 2) (Level 3) Total Liabilities: Convertible notes $ — $ — $ 4,179 $ 4,179 Liability classified warrants — — 2,307 2,307 Total $ — $ — $ 6,486 $ 6,486
Summary of Changes in Forward Option and Convertible Notes Derivative Liability	The following table presents the changes in the forward option-prepaid forward contracts, convertible notes measured at fair value, warrants liability, and the notes derivative liability for the periods ended June 30, 2024 and December 31, 2023 (in thousands): Level 3 Roll Forward Convertible Notes Liability Classified Warrants Balance as of December 31, 2023 $ 4,373 $ 2,307 Additions 501 586 Cash paid to settle ( 700 ) — Exchange for short-term note payable — ( 450 ) Shares issued upon conversion or exercise ( 4,922 ) ( 3,106 ) Changes in fair value 748 966 Balance as of June 30, 2024 $ — $ 303
Schedule of Significant Assumptions Valuing of Fair Value	The liability classified warrants as of June 30, 2024 and December 31, 2023, include three classes of warrants, and therefore, the range of assumptions used has been provided. Significant assumptions used in valuing warrants which require liability classification were as follows as of June 30, 2024 and December 31, 2023. As of June 30, 2024 Expected volatility 115.00 % Equivalent term (#) 3.33 Risk-free rate 4.37 % Dividend yield 0.00 % Stock price $ 7.59 Strike price (#) $ 287.50 As of December 31, 2023 Minimum Maximum Expected volatility 85.00 % 90.00 % Equivalent term 4.04 4.65 Risk-free rate 3.84 % 3.90 % Dividend yield 0.00 % 0.00 % Stock price $ 0.44 $ 0.44 Strike price $ 0.50 $ 11.50

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Summary of Weighted-Average Outstanding Shares	The following weighted-average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive: As of June 30, 2024 2023 Investor D warrants — 21,891 Investor E warrants 650,446 — Placement Agent warrants 21,682 — Public Stockholders' warrants 422,000 422,000 Private Placement warrants 229,520 229,520 PIPE Investor warrants 20,000 20,000 Legacy warrants 1,957 1,957 Employee based options to purchase common stock 22,653 23,833 Unvested employee based restricted stock units 40,068 8,741 Total 1,408,326 727,942
Summary of Weighted Average Shares Outstanding for Basic and Diluted Net Loss Per Share	The following table presents the calculation of basic and diluted net loss per share (in thousands except share and per share information): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss $ ( 3,236 ) $ ( 2,447 ) $ ( 15,933 ) $ ( 9,543 ) Weighted-average shares outstanding - basic and diluted 3,154,782 597,315 2,975,248 559,385 Basic and diluted net loss per share $ ( 1.03 ) $ ( 4.10 ) $ ( 5.36 ) $ ( 17.06 )

Description of Business - Addit

Description of Business - Additional Information (Details) $ / shares in Units, shares in Thousands, $ in Thousands		6 Months Ended
	Jun. 07, 2024 $ / shares shares	Jun. 30, 2024 USD ($) $ / shares	Dec. 31, 2023 USD ($) $ / shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit | $		$ 130,667	$ 114,734
Cash | $		$ 1,179	$ 176
Reverse stock split, description		On June 7, 2024, the Company effected a 1-for-25 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock, par value $0.0001 (the "common stock"). Following the effect of the Reverse Stock Split, every 25 shares of the Company’s common stock that were issued and outstanding automatically converted into one outstanding share of common stock
Common stock, par value | $ / shares		$ 0.0001	$ 0.0001
Outstanding warrants | shares	16,788,000
Warrant exercise price | $ / shares	$ 11.5	$ 22.83
Conversion ratio	0.04

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Accrued bonus	$ 856	$ 501
Accrued director compensation	610	427
Accrued research and development	502	507
Accrued legal	118	43
Accrued interest	75	19
Other	97	26
Total accrued expenses	$ 2,258	$ 1,523

Revenues and Contract Obligat_3

Revenues and Contract Obligations - Summary of Changes in the Contract Liability (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Revenue from Contract with Customer [Abstract]
Contract liabilities, beginning of period	$ 0
Consideration received and deferred	550
Contract liabilities, end of period	$ 550

Revenues and Contract Obligat_4

Revenues and Contract Obligations - Summary of Expected Recognition of Revenue From Contract Liabilities (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 550
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 56
Revenue, remaining performance obligation, expected timing of satisfaction, period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 112
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 112
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 112
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 112
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2029-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 46
Revenue, remaining performance obligation, expected timing of satisfaction, period

Revenues and Contract Obligat_5

Revenues and Contract Obligations - Summary of Expected Recognition of Revenue From Contract Liabilities (Details1) $ in Thousands	Jun. 30, 2024 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 550

Revenues and Contract Obligat_6

Revenues and Contract Obligations - Additional Information (Details) - License and Distribution Agreement [Member] $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Disaggregation of Revenue [Line Items]
Proceeds from upfront payment	$ 0.1
Sales Based Milestone [Member]
Disaggregation of Revenue [Line Items]
Proceeds from milestone payment	0.3
Regulatory Milestone [Member]
Disaggregation of Revenue [Line Items]
Proceeds from milestone payment	$ 0.5

Notes Payable - Summary of Note

Notes Payable - Summary of Notes payable (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Notes Payable [Line Items]
Payments	$ (2,075)	$ (2,946)
Amortization of costs	57	$ 23
LMFA [Member]
Notes Payable [Line Items]
Notes payable, Balance	296
Payments	(296)
LMFAO [Member]
Notes Payable [Line Items]
Notes payable, Balance	1,128
Payments	(1,128)
Maxim [Member]
Notes Payable [Line Items]
Notes payable, Balance	2,771
Payments	(181)
Notes payable, Balance	2,590
Insurance Financing [Member]
Notes Payable [Line Items]
Notes payable, Balance	565
Payments	(420)
Notes payable, Balance	145
Investor D Note [Member]
Notes Payable [Line Items]
Notes payable, Balance	0
Note issued in exchange for warrants	450
Payments	0
Notes payable, Balance	450
Unamortized deferred financing costs member
Notes Payable [Line Items]
Unamortized deferred financing costs, Balance	(52)
Payments	(50)
Amortization of costs	57
Unamortized deferred financing costs, Balance	$ (45)

Notes Payable - Future Maturiti

Notes Payable - Future Maturities of Principal Repayment of Convertible Notes (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Notes Payable [Abstract]
2024 (remaining)	$ 3,185
Thereafter	0
Total	$ 3,185

Notes Payable - Investor D Note

Notes Payable - Investor D Note - Additional Information (Details) - Investor D Note [Member] $ in Millions	Jun. 28, 2024 USD ($)
Notes Payable [Line Items]
Short-term note	$ 0.5
Interest rate on the loan	7%

Notes Payable - Senior Secured

Notes Payable - Senior Secured LMFA Notes Payable - Additional Information (Details) - Senior Secured LMFA Notes Payable [Member]	6 Months Ended
	Jun. 30, 2024
Notes Payable [Line Items]
Debt instrument, interest rate	7%
Debt instrument, maturity date	Mar. 27, 2025

Notes Payable - Senior Secure_2

Notes Payable - Senior Secured LMFAO Note Payable - Additional Information (Details) - Senior Secured LMFAO Note Payable [Member]	6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024
Notes Payable [Line Items]
Debt instrument, maturity date	Mar. 27, 2025
Debt instrument, interest rate		7%

Notes Payable - Unsecured Maxim

Notes Payable - Unsecured Maxim Note Payable - Additional Information (Details) - Unsecured Maxim Note Payable [Member] - USD ($) $ in Millions	1 Months Ended
	Oct. 31, 2022	Jun. 30, 2024
Notes Payable LineItems
Professional fees	$ 4.2
Debt instrument, interest rate		7%
Remaining contractual balance		$ 2.6
Reverse stock split maxim note due	90 days

Notes Payable - Insurance Finan

Notes Payable - Insurance Financing - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Oct. 31, 2023	Jun. 30, 2024
Notes Payable [Line Items]
Annual premium of insurance policy amount	$ 0.7
Frequency of principal and interest payments		two monthly
Payment terms		The Company will pay the remaining two monthly installments of principal and interest with the last payment being made in August 2024

Convertible Notes - Activity fo

Convertible Notes - Activity for the Convertible Notes (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Jun. 05, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Debt Instrument [Line Items]
Balance				$ 4,373
Issuance (Face Value)				1,087
Fair value of detachable warrants at issuance		$ (1,880)	$ (723)	966	$ (759)
(Gain)/loss on conversion				5,397
Conversion to common stock				(10,319)
(Gain)/loss on reporting period remeasurement				748
Redemption	$ (700)			(700)	$ (258)
Balance		0		0
Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				(586)
3rd Investor D Note 3-1
Debt Instrument [Line Items]
Balance				1,012
Issuance (Face Value)				0
(Gain)/loss on conversion				1,201
Conversion to common stock				(2,213)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		0		0
3rd Investor D Note 3-1 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				0
3rd Investor D Note 3-2
Debt Instrument [Line Items]
Balance				999
Issuance (Face Value)				0
(Gain)/loss on conversion				636
Conversion to common stock				(1,635)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		0		0
3rd Investor D Note 3-2 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				0
3rd Investor D Note 3-3
Debt Instrument [Line Items]
Balance				972
Issuance (Face Value)				0
(Gain)/loss on conversion				615
Conversion to common stock				(1,587)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		0		0
3rd Investor D Note 3-3 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				0
3rd Investor D Note 3-4
Debt Instrument [Line Items]
Balance				568
Issuance (Face Value)				0
(Gain)/loss on conversion				381
Conversion to common stock				(949)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		0		0
3rd Investor D Note 3-4 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				0
4th Investor D Note
Debt Instrument [Line Items]
Balance				822
Issuance (Face Value)				0
(Gain)/loss on conversion				77
Conversion to common stock				(947)
(Gain)/loss on reporting period remeasurement				748
Redemption				(700)
Balance		0		0
4th Investor D Note | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				0
5th Investor D Note
Debt Instrument [Line Items]
Balance				0
Issuance (Face Value)				272
(Gain)/loss on conversion				482
Conversion to common stock				(607)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		0		0
5th Investor D Note | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				(147)
6th Investor D Note
Debt Instrument [Line Items]
Balance				0
Issuance (Face Value)				815
(Gain)/loss on conversion				2,005
Conversion to common stock				(2,381)
(Gain)/loss on reporting period remeasurement				0
Redemption				0
Balance		$ 0		0
6th Investor D Note | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance				$ (439)

Convertible Notes - Additional

Convertible Notes - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands							3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 05, 2024	Apr. 01, 2024	Jan. 30, 2024	Jan. 24, 2024	Jan. 12, 2024	Mar. 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 07, 2024	Jan. 26, 2024
Debt Instrument [Line Items]
Initial conversion price					$ 14
Warrant exercise price	$ 22.83							$ 22.83		$ 11.5
Additional warrants to purchase											21,682
Loss on extinguishment of convertible notes							$ 5,800
Loss on coversion into equity							4,700
Debt conversion, original debt amount	$ 0
Conversion of outstanding debt to common stock								$ 10,319
Suspention period			60 days
Investment right notice period			10 days
Percentage Of Conversion Amount			200%
Redeemed outstanding convertible debt		$ 700						$ 700	$ 258
Investor D Convertible Notes And Warrant Activity [Member]
Debt Instrument [Line Items]
Issuing notes in principal amounts					$ 800	$ 300
Interest rate of senior unsecured convertible note issued					7%	7%
Maturity date					Apr. 24, 2025	Apr. 12, 2025
Common Stock [Member] | Investor D Convertible Notes And Warrant Activity [Member]
Debt Instrument [Line Items]
Issued warrants to purchase					15,382
Warrant exercise price					$ 14	$ 14
Additional warrants to purchase					15,382
Maximum [Member] | Common Stock [Member] | Investor D Convertible Notes And Warrant Activity [Member]
Debt Instrument [Line Items]
Issued warrants to purchase						5,278
Additional warrants to purchase						5,278
Convertible Notes [Member] | Investor Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount							1,000
Optional debt redemption rights suspension period				60 days
Debt redemption percentage				200%
Debt conversion, original debt amount							3,300
Conversion of outstanding debt to common stock							9,500
Fair value of convertible notes							1,100
Investor D Convertible Notes [Member]
Debt Instrument [Line Items]
Losses on issuance of the convertible notes							700
Conversion of outstanding debt to common stock							$ 400
Investor D Convertible Notes [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Losses on issuance of the convertible notes		400
Debt conversion, original debt amount		600
Debt Conversion, Accrued interest, Amount		$ 700
Debt Conversion Shares Issued		92,858

Equity Transactions - Additiona

Equity Transactions - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended		12 Months Ended
	Jan. 26, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jun. 07, 2024
Class of Warrant or Right [Line Items]
Warrant exercise price		$ 22.83			$ 11.5
Warrants to purchase Common stock	21,682
Warrants issued fair value	$ 300
Placement agent fee paid		$ 700
Warrant exerciseable date		Jul. 30, 2024
Proceeds from issuance of shares		$ 4,492	$ 1,163
Amount available to draw				$ 95,300
Tumim Stone Capital [Member]
Class of Warrant or Right [Line Items]
Shares issued				6,500,000
Proceeds from issuance of shares				$ 4,700
Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 0.0001
Warrants to purchase Common stock	252,182
Aggregate gross proceeds	$ 9,000
Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 20.76
Series A Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock	433,631
Series B Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock	216,816
Pre-funded Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 0.0001
Warrants to purchase Common stock	181,449

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended		6 Months Ended
	Jan. 30, 2024	Jan. 28, 2024	Jan. 24, 2024	Jan. 12, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 07, 2024	Jan. 26, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock										21,682
Warrants initial exercise price					$ 22.83		$ 22.83		$ 11.5
Fair value of detachable warrants at issuance					$ (1,880)	$ (723)	$ 966	$ (759)
Exchange of Outstanding warrant							10,319
Liability Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value of detachable warrants at issuance							$ 600
Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock										252,182
Warrants initial exercise price										$ 0.0001
Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants initial exercise price										$ 20.76
Pre-funded Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock										181,449
Warrants initial exercise price										$ 0.0001
Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase common stock from total shares percentage	5%
Warrants exercisable at price equal to offering price percentage							110%
Private Placement Warrants [Member] | Liability Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants initial exercise price					$ 287.5		$ 287.5				$ 287.5
Series A Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock										433,631
Series B Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock										216,816
Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants exchanged for short term notes payable		$ 500
Gain (loss) on exercises							$ (1,600)
Investor D Warrants [Member] | Liability Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants initial exercise price											$ 12.5
Exchange With Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Gain (loss) on exercises							$ 1,300
Short Term Investor D Note [Member]
Class of Warrant or Right [Line Items]
Exchange of Outstanding warrant					$ 500
Gain on exchange of warrant					1,300
Unrealized gain on Exchange of warrant					$ 600
Placement Agent Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock	21,682									21,682
Warrants initial exercise price										$ 22.83
Warrants expiry date	Jan. 30, 2029
Investor D Convertible Notes And Warrant Activity [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants initial exercise price			$ 0.56	$ 0.56
Investor D Convertible Notes And Warrant Activity [Member] | Common Stock [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Issued warrants to purchase			395,781	131,927
Warrants to purchase Common stock			395,781	131,927

Warrants - Schedule of Warrants

Warrants - Schedule of Warrants Outstanding (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Warrants outstanding	$ 1,345,605	$ 928,209
Liability Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	249,520	504,252
Liability Classified Warrants [Member] | Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	0	254,732
Liability Classified Warrants [Member] | Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	229,520	229,520
Liability Classified Warrants [Member] | PIPE Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	20,000	20,000
Equity Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,096,085	423,957
Equity Classified Warrants [Member] | Investor E Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	650,446	0
Equity Classified Warrants [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	21,682	0
Equity Classified Warrants [Member] | Public Stockholders Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	422,000	422,000
Equity Classified Warrants [Member] | Legacy Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	$ 1,957	$ 1,957

Warrants - Schedule of Weighted

Warrants - Schedule of Weighted-Average Strike Price and Time to Maturity for Each Warrant Tranche (Details) - $ / shares	Jun. 30, 2024	Jun. 07, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Warrant Share Equivalents		16,788,000,000
Weighted-Average Strike Price	$ 22.83	$ 11.5
Liability Classified Warrants [Member] | Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents			254,732
Weighted-Average Strike Price			$ 12.5
Weighted-Average Time to Expiration			4 years 7 months 24 days
Liability Classified Warrants [Member] | Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	229,520		229,520
Weighted-Average Strike Price	$ 287.5		$ 287.5
Weighted-Average Time to Expiration	3 years 3 months 25 days		3 years 9 months 25 days
Liability Classified Warrants [Member] | PIPE Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	20,000		20,000
Weighted-Average Strike Price	$ 287.5		$ 287.5
Weighted-Average Time to Expiration	3 years 3 months 25 days		3 years 9 months 25 days
Equity Classified Warrants [Member] | Investor E Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	650,446
Weighted-Average Strike Price	$ 20.76
Weighted-Average Time to Expiration	4 years 11 months 4 days
Equity Classified Warrants [Member] | Placement Agent warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	21,682
Weighted-Average Strike Price	$ 22.75
Weighted-Average Time to Expiration	4 years 6 months 29 days
Equity Classified Warrants [Member] | Public Stockholders Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	422,000		422,000
Weighted-Average Strike Price	$ 287.5		$ 287.5
Weighted-Average Time to Expiration	3 years 3 months 29 days		3 years 9 months 25 days
Equity Classified Warrants [Member] | Legacy SeaStar Inc. Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	1,957		1,957
Weighted-Average Strike Price	$ 250		$ 250
Weighted-Average Time to Expiration	1 year 10 months 17 days		2 years 4 months 17 days

Warrants - Schedule of Warrant

Warrants - Schedule of Warrant Activity (Details)	6 Months Ended
	Jun. 30, 2024 shares
Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	254,732
Issuance	42,217
Exercised	(170,625)
Forfeited/cancelled	0
Exchanged for Investor D Note	(126,324)
Outstanding Balance	0
Investor E Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	0
Issuance	831,895
Exercised	(181,449)
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	650,446
Placement Agent warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	0
Issuance	21,682
Exercised	0
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	21,682
Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	229,520
Issuance	0
Exercised	0
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	229,520
PIPE Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	20,000
Issuance	0
Exercised	0
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	20,000
Public Stockholders Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	422,000
Issuance	0
Exercised	0
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	422,000
Legacy Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	1,957
Issuance	0
Exercised	0
Forfeited/cancelled	0
Exchanged for Investor D Note	0
Outstanding Balance	1,957

Stock-Based Compensation Awar_3

Stock-Based Compensation Awards - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 41	$ 555	$ 475	$ 1,060
Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	(7)	96	112	135
General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 48	$ 459	$ 363	$ 925

Stock-Based Compensation Awar_4

Stock-Based Compensation Awards - Additional Information (Details) - Key Employees and Non-Employee Service Providers [Member] - 2022 Omnibus Incentive Plan [Member]	6 Months Ended
	Jun. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options expiration period	10 years
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	1 year
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	4 years

Stock-Based Compensation Awar_5

Stock-Based Compensation Awards - Summary of Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
2022 Omnibus Incentive Plan - Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance, Outstanding	14,045
Exercised	0
Issued	0
Forfeited / cancelled	(266)
Ending balance, Outstanding	13,779	14,045
Vested and exercisable	13,779
Weighted Average Exercise Price
Beginning balance, Outstanding	$ 46
Ending balance, Outstanding	46	$ 46
Vested and exercisable	$ 0
Total Intrinsic Value
Outstanding	$ 0	$ 0
Vested and exercisable	$ 0
Weighted Average Remaining Contractual Life (Years)
Outstanding	8 years 9 months 18 days	8 years 9 months 18 days
Vested and exercisable	8 years 9 months 18 days
2019 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance, Outstanding	9,792
Exercised	0
Issued	0
Forfeited / cancelled	(160)
Ending balance, Outstanding	9,632	9,792
Vested and exercisable	8,874
Weighted Average Exercise Price
Beginning balance, Outstanding	$ 46
Ending balance, Outstanding	46	$ 46
Vested and exercisable	$ 46
Total Intrinsic Value
Outstanding	$ 0	$ 0
Vested and exercisable	$ 0
Weighted Average Remaining Contractual Life (Years)
Outstanding	6 years 2 months 12 days	6 years 4 months 24 days
Vested and exercisable	6 years 2 months 12 days

Stock-Based Compensation Awar_6

Stock-Based Compensation Awards - Summary of RSU Activity (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2024 $ / shares shares
2022 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Beginning Balance, Outstanding	9,372
Granted	38,000
Vested	(9,194)
Forfeited / cancelled	(178)
Ending Balance, Outstanding	38,000
Beginning Balance, Outstanding | $ / shares	$ 36.75
Ending Balance, Outstanding | $ / shares	$ 17.93
2019 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Beginning Balance, Outstanding	3,698
Exercised	0
Vested	(1,278)
Forfeited / cancelled	(352)
Ending Balance, Outstanding	2,068
Beginning Balance, Outstanding | $ / shares	$ 200
Ending Balance, Outstanding | $ / shares	$ 200

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Loss Contingencies [Line Items]
Legal settlement in accrued expenses					$ 200
Rent expense	$ 8	$ 16	$ 8	$ 16

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	$ 303	$ 6,486
Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	4,179
Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	303	2,307
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 1 [Member] | Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 1 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2 [Member] | Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	303	6,486
Level 3 [Member] | Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	4,179
Level 3 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	$ 303	$ 2,307

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Changes in Forward Option and Convertible Notes Derivative Liability (Detail) - Level 3 [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Convertible Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 4,373
Additions	501
Cash paid to settle	(700)
Exchange for short-term note payable	0
Shares issued upon conversion or exercise	(4,922)
Changes in fair value	748
Balance	0
Liability Classified Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	2,307
Additions	586
Cash paid to settle	0
Exchange for short-term note payable	(450)
Shares issued upon conversion or exercise	(3,106)
Changes in fair value	966
Balance	$ 303

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Significant Assumptions Valuing of Fair Value (Details) - Warrants [Member]	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Expected Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	115
Expected Volatility [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		90
Expected Volatility [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		85
Equivalent Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equivalent term	3 years 3 months 29 days
Equivalent Term [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equivalent term	4 years 7 months 24 days
Equivalent Term [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equivalent term	4 years 14 days
Risk-Free Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	4.37
Risk-Free Rate [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		3.9
Risk-Free Rate [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		3.84
Dividend Yield [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0
Dividend Yield [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		0
Dividend Yield [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		0
Stock Price [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	7.59
Stock Price [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		0.44
Stock Price [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		0.44
Strike price [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	287.5
Strike price [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		11.5
Strike price [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input		0.5

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Maximum [Member]
Schedule of Income Taxes [Line Items]
Provision for certain minimum state taxes	$ 0.1	$ 0.1

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Earnings Per Share Basic And Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Net loss	$ (3,236)	$ (12,697)	$ (2,447)	$ (7,096)	$ (15,933)	$ (9,543)
Weighted-average shares outstanding - basic	3,154,782		597,315		2,975,248	559,385
Basic net loss per share	$ (1.03)		$ (4.1)		$ (5.36)	$ (17.06)
Weighted-average shares outstanding - diluted	3,154,782		597,315		2,975,248	559,385
Diluted net loss per share	$ (1.03)		$ (4.1)		$ (5.36)	$ (17.06)

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Weighted-Average Outstanding Shares (Detail) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,408,326	727,942
Investor D Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	0	21,891
Investor E Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	650,446	0
Placement Agent warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	21,682	0
Public Stockholders Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	422,000	422,000
Private Placement Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	229,520	229,520
PIPE Investor Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	20,000	20,000
Legacy (Pre-merger) Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,957	1,957
Employee Based Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	22,653	23,833
Unvested Employee Based Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	40,068	8,741

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Sep. 07, 2024	Jul. 10, 2024	Jun. 07, 2024	Jan. 26, 2024	Jun. 30, 2024
Subsequent Event [Line Items]
Warrants to purchase Common stock				21,682
Warrant exercise price			$ 11.5		$ 22.83
Maxim Note Payable Payment [Member]
Subsequent Event [Line Items]
Repayments of Debt			$ 2.5
Investor D Note [Member]
Subsequent Event [Line Items]
Debt redemption and conversion maximum due period			90 days
Common Stock [Member]
Subsequent Event [Line Items]
Warrants to purchase Common stock				252,182
Warrant exercise price				$ 0.0001
Aggregate gross proceeds				$ 9
Private Placement [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Warrant exercise price				$ 20.76
Scenario Forecast [Member] | Maxim Note Payable Payment [Member]
Subsequent Event [Line Items]
Repayments of Debt	$ 0.1
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Warrants to purchase Common stock		947,868
Aggregate gross proceeds		$ 10
Subsequent Event [Member] | Common Warrants [Member]
Subsequent Event [Line Items]
Warrant exercise price		$ 10.55
Warrants expire		5 years
Common warrants maturity due		30 days
Subsequent Event [Member] | Common Warrants [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Warrant exercise price		$ 10.55
Subsequent Event [Member] | Common Warrants [Member] | Private Placement [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Warrants to purchase Common stock		947,868